Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01197560 · ClinicalTrials.gov registry record · Phase 2
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase 2 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
NCT01197560 is a Phase 2 study that has completed, run by Celgene. The registered enrollment target is 111 participants.
The verdict
NCT01197560, a Phase 2 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
Study Summary
The purpose of this study is to compare lenalidomide to a control drug and see which one delays Diffuse Large B-Cell Lymphoma (DLBCL) disease progression longer.
Interventions
- DRUG Oxaliplatin
- DRUG Rituximab
- DRUG Etoposide
- DRUG Lenalidomide
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2010-09-02 |
| Est. Completion | 2018-04-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01197560
The ClinicalTrials.gov registry entry for NCT01197560 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Oxaliplatin is the first listed.
NCT01197560 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01197560 about?
NCT01197560 is a clinical study titled "Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)". The purpose of this study is to compare lenalidomide to a control drug and see which one delays Diffuse Large B-Cell Lymphoma (DLBCL) disease progression longer.
What is the current status of trial NCT01197560?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2010-09-02. Estimated completion is 2018-04-05.
What interventions are being tested in trial NCT01197560?
The interventions under investigation include: Oxaliplatin (DRUG), Rituximab (DRUG), Etoposide (DRUG), Lenalidomide (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT01197560?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.